IL-TEC-0278, MAY 25

Yescarta is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Limitation of Use: Yescarta is not indicated for the treatment of patients with primary or secondary central nervous system lymphoma. Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Tecartus® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor unless ineligible to BTK inhibitor
Limitation of use: Tecartus® is not indicated for the treatment of patients with active central nervous system lymphoma.
Tecartus® is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

The pictures on the website are for illustration purposes (AI generated).

For further information and full list of adverse events, please refer to the approved prescribing information as available at Israeli Ministry of Health website : https://israeldrugs.health.gov.il/#!/byDrug
Report an AE https://www.gileadisrael.co.il/utility/contact
This casestudy is intended for healthcare providers only
For any further questions please contact: medinfo.israel@gilead.com
© Gilead Sciences Israel Ltd. All rights reserved